Keyphrases
Kidney
100%
Large-scale Clinical Trial
100%
Composite Outcome
100%
Cardio
100%
Kidney Disease
75%
Heart Failure with Preserved Ejection Fraction (HFpEF)
75%
Heart Failure
50%
Diabetes
50%
Without Diabetes
50%
Cardiac Disease
50%
Kidney Outcomes
50%
Sacubitril-valsartan
50%
Risk Reduction
25%
Clinically Significant
25%
Cardiovascular Outcomes
25%
Chronic Kidney Disease
25%
Clinical Presentation
25%
Comorbid
25%
Novel Treatments
25%
Beneficial Effects
25%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
25%
Acute Cardiovascular Events
25%
Disease Risk Factors
25%
Obesity-related Hypertension
25%
Renal Function Improvement
25%
Complex Interplay
25%
Trial Results
25%
Patients with Chronic Heart Failure
25%
Cardiac Outcomes
25%
Established Cardiovascular Disease
25%
Cardiovascular Outcome Trials
25%
Atherosclerotic Vascular Disease
25%
Potential Challenges
25%
Vascular Disease Risk
25%
Chronic Cardiovascular Diseases
25%
Chronic Metabolic Diseases
25%
Medicine and Dentistry
Diabetes
100%
Congestive Heart Failure
100%
Clinical Trial
100%
Nephropathy
75%
Cardiovascular System
75%
Cardiovascular Disease
50%
Heart Disease
50%
Heart Failure with Reduced Ejection Fraction
50%
Sacubitril
50%
Valsartan
50%
Diseases
25%
Water-Electrolyte Imbalance
25%
Chronic Kidney Disease
25%
Kidney Function
25%
Post-Hoc Analysis
25%
Risk Reduction
25%
Heart Failure with Preserved Ejection Fraction
25%
Sodium Glucose Cotransporter 2 Inhibitor
25%
Vascular Disease
25%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Congestive Heart Failure
100%
Kidney Disease
75%
Valsartan/Sacubitril
50%
Heart Failure with Reduced Ejection Fraction
50%
Heart Disease
50%
Cardiovascular Disease
50%
Heart Failure with Preserved Ejection Fraction
25%
Metabolic Disorder
25%
Chronic Kidney Failure
25%
Sodium Glucose Cotransporter 2 Inhibitor
25%
Disease
25%
Vascular Disease
25%